Azitra, Inc. (NYSE: AZTR)

Azitra, Inc. is an early stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The company has built a proprietary platform that includes a microbial library of approximately 1,500 unique bacterial strains isolated from human skin. This library is screened using artificial intelligence and machine learning tools developed in collaboration with researchers from Carnegie Mellon University to predict drug like molecules. A licensed genetic engineering technology from the Fred Hutchinson Cancer Center enables modification of previously intractable strains, expanding the range of microbes that can be engineered. Azitra’s lead product candidates are ATR 12 for Netherton syndrome, ATR 04 for EGFRi associated rash, and ATR 01 for ichthyosis vulgaris, each based on a genetically modified strain of Staphylococcus epidermidis designed to deliver therapeutic proteins directly to the skin.

Azitra, Inc. has not commenced commercial operations and does not generate revenue from product sales. The company has reported minimal service revenue related to research collaborations, such as a joint development agreement with Bayer that yielded seven thousand five hundred dollars in 2024 but none in 2025. Its primary financial support has come from a series of equity offerings, including an initial public offering in June 2023 and subsequent follow on placements, as well as draws on an equity line of credit with Alumni Capital LP. Until its pipeline candidates receive regulatory approval and reach the market, revenue generation will remain limited to these financing activities and occasional service income.

Azitra, Inc. occupies a pioneering niche in the field of live biotherapeutic products for dermatology, being among the first to engineer commensal skin bacteria for therapeutic use. The company’s pipeline targets rare and prevalent skin conditions that currently lack approved disease modifying therapies. For Netherton syndrome, competitors include Sixera Pharma which is investigating SXR 1096 and Quoin Pharmaceuticals which is investigating QRX 003, while for EGFRi associated rash emerging candidates are Hoth Therapeutics with HT 001 and Lutris Pharma with LUT 014. In the broader ichthyosis vulgaris market, most treatments are limited to symptomatic moisturizers and keratolytics, leaving a clear opening for a disease modifying approach. Azitra’s competitive advantages stem from its proprietary microbial library of over 1,500 strains, its AI/ML driven screening platform that predicts bioactive molecules from genetic sequences, and its exclusive worldwide license to the Fred Hutchinson Cancer Center’s SMPL technology, which enables genetic modification of previously intractable microbes. Together these capabilities allow the company to rapidly identify and engineer therapeutic candidates that few rivals can replicate, supporting a potential multi hundred million dollar opportunity for each lead program as noted in its internal projections.

The company intends to serve patients diagnosed with rare dermatologic conditions such as Netherton syndrome, EGFRi associated rash, and ichthyosis vulgaris, as well as the dermatologists and healthcare providers who treat these individuals. Based on publicly available estimates, Netherton syndrome affects roughly one to nine per hundred thousand people, which translates to a few thousand individuals in the United States alone. EGFRi associated rash occurs in up to eighty percent of patients receiving epidermal growth factor receptor inhibitor therapy for cancers such as colorectal or head and neck malignancies, representing a sizable subset of the hundreds of thousands of patients treated annually with these agents. Ichthyosis vulgaris has an estimated prevalence of one in two hundred fifty, corresponding to approximately 1.3 million people in the United States. While no commercial sales have occurred to date, the company’s future customer base will include patients seeking disease modifying therapies, physicians looking for effective adjunctive treatments, and payers interested in reducing the burden of chronic skin disease. Specific customer names have not been disclosed because the company remains in the pre revenue development stage.